Compare Stocks: HCM, CRNX, BLTE, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$170.96 +0.4%	$163.39	$68.21 ▼ $200.00	$6.88B	-1.23	201,330 shs	93,895 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.41	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
HCM HUTCHMED	$13.67 -1.1%	$12.26	$9.77 ▼ $17.29	$2.38B	0.24	93,236 shs	15,795 shs
LNTH Lantheus	$100.55 -0.2%	$101.75	$49.67 ▼ $111.86	$6.56B	-0.03	965,787 shs	1.03 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+0.36%	-1.63%	+1.43%	+17.00%	+134.19%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+0.31%	+136.83%	+148.39%
HCM HUTCHMED	-1.09%	+6.63%	+8.58%	+32.98%	-21.80%
LNTH Lantheus	-0.25%	+0.30%	+0.07%	-3.24%	+97.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$170.96 +0.4%	$163.39	$68.21 ▼ $200.00	$6.88B	-1.23	201,330 shs	93,895 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.41	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
HCM HUTCHMED	$13.67 -1.1%	$12.26	$9.77 ▼ $17.29	$2.38B	0.24	93,236 shs	15,795 shs
LNTH Lantheus	$100.55 -0.2%	$101.75	$49.67 ▼ $111.86	$6.56B	-0.03	965,787 shs	1.03 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+0.36%	-1.63%	+1.43%	+17.00%	+134.19%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+0.31%	+136.83%	+148.39%
HCM HUTCHMED	-1.09%	+6.63%	+8.58%	+32.98%	-21.80%
LNTH Lantheus	-0.25%	+0.30%	+0.07%	-3.24%	+97.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.64	Moderate Buy	$218.73	27.94% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.65% Downside
HCM HUTCHMED	2.43	Hold	$14.87	8.75% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.52% Upside

Current Analyst Ratings Breakdown

Latest HCM, CRNX, BLTE, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/8/2026	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/3/2026	BLTE Belite Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$214.00 ➝ $245.00
9/3/2026	HCM HUTCHMED	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/2/2026	CRNX Crinetics Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
HCM HUTCHMED	$548.51M	4.35	$2.66 per share	5.13	$7.17 per share	1.91
LNTH Lantheus	$1.54B	4.26	$6.37 per share	15.79	$16.43 per share	6.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	187.87	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
HCM HUTCHMED	$456.91M	N/A	N/A	62.14	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	$233.56M	$4.14	24.29	18.42	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)

Latest HCM, CRNX, BLTE, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
HCM HUTCHMED	0.06	5.64	5.50
LNTH Lantheus	0.43	3.06	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CRNX Crinetics Pharmaceuticals	98.51%
HCM HUTCHMED	8.82%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CRNX Crinetics Pharmaceuticals	3.80%
HCM HUTCHMED	3.60%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable

HCM, CRNX, BLTE, and LNTH Headlines

Recent News About These Companies

California State Teachers Retirement System Sells 2,182 Shares of Lantheus Holdings, Inc. $LNTH

September 13, 2026 | marketbeat.com

Hsbc Holdings PLC Invests $2.27 Million in Lantheus Holdings, Inc. $LNTH

September 12, 2026 | marketbeat.com

Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?

September 11, 2026 | aol.comA

2 Small-Cap Stocks to Consider Right Now and 1 That Underwhelm

September 11, 2026 | msn.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of "Hold" from Analysts

September 11, 2026 | americanbankingnews.com

Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH

September 10, 2026 | businesswire.com

Carmignac Gestion Has $148.67 Million Holdings in Lantheus Holdings, Inc. $LNTH

September 8, 2026 | marketbeat.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of "Hold" from Brokerages

September 6, 2026 | marketbeat.com

The Pharma Letter M&A round-up – August 2026

September 2, 2026 | thepharmaletter.comT

SkyOak Wealth LLC Reduces Stake in Lantheus Holdings, Inc. $LNTH

September 2, 2026 | marketbeat.com

Legal & General Group Plc Takes $9.79 Million Position in Lantheus Holdings, Inc. $LNTH

September 1, 2026 | marketbeat.com

20,539 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Hsbc Holdings PLC

August 31, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Makes New $6.85 Million Investment in Lantheus Holdings, Inc. $LNTH

August 31, 2026 | marketbeat.com

Penn Capital Management Company LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

August 30, 2026 | marketbeat.com

Cookson Peirce & Co. Inc. Takes $2.67 Million Position in Lantheus Holdings, Inc. $LNTH

August 30, 2026 | marketbeat.com

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

25,131 Shares in Lantheus Holdings, Inc. $LNTH Bought by Formula Growth Ltd.

August 28, 2026 | marketbeat.com

Summit Street Capital Management LLC Purchases New Holdings in Lantheus Holdings, Inc. $LNTH

August 27, 2026 | marketbeat.com

Curium acquisition of Lantheus backed by $5.375B of debt financing

August 26, 2026 | finance.yahoo.com

Jupiter Topco LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

August 26, 2026 | marketbeat.com

Expect Equity LLC Takes $3.56 Million Position in Lantheus Holdings, Inc. $LNTH

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM, CRNX, BLTE, and LNTH Company Descriptions

Belite Bio NASDAQ:BLTE

$170.96 +0.61 (+0.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$171.18 +0.22 (+0.13%)

As of 09/18/2026 07:30 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$13.67 -0.15 (-1.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.64 -0.03 (-0.25%)

As of 09/18/2026 07:30 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Lantheus NASDAQ:LNTH

$100.55 -0.25 (-0.25%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$100.27 -0.28 (-0.28%)

As of 09/18/2026 07:30 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HCM, CRNX, BLTE, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HCM, CRNX, BLTE, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HCM, CRNX, BLTE, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM, CRNX, BLTE, and LNTH Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

HUTCHMED NASDAQ:HCM

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HCM, CRNX, BLTE, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HCM, CRNX, BLTE, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HCM, CRNX, BLTE, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM, CRNX, BLTE, and LNTH Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

HUTCHMED NASDAQ:HCM

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools